A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of AFQ056 in adolescent patients with Fragile X Syndrome

Trial Profile

A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of AFQ056 in adolescent patients with Fragile X Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs Mavoglurant (Primary)
  • Indications Fragile X syndrome
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Aug 2017 This trial has been Discontinued in Belgium, according to European Clinical Trials Database
    • 10 Jun 2017 Biomarkers information updated
    • 12 May 2014 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top